First Time Loading...

Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 277.37 USD 1.25% Market Closed
Updated: May 2, 2024
AMGN
/
Income Statement
/
Revenue

Amgen Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amgen Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
MRNA
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Moderna Inc
NASDAQ:MRNA
Revenue
$6.8B
CAGR 3-Years
104%
CAGR 5-Years
119%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Amgen Inc
Revenue Breakdown

Breakdown by Geography
Amgen Inc

Total Revenue: 28.2B USD
100%
United States: 19.8B USD
70.3%
Row: 8.4B USD
29.7%

Breakdown by Segments
Amgen Inc

Total Revenue: 28.2B USD
100%
Other Products: 5.3B USD
18.7%
Prolia: 4B USD
14.4%
Enbrel: 3.7B USD
13.1%
Otezla: 2.2B USD
7.8%
Xgeva: 2.1B USD
7.5%
Repatha: 1.6B USD
5.8%
Nplate: 1.5B USD
5.2%
Kyprolis: 1.4B USD
5%
Aranesp: 1.4B USD
4.8%
Other Revenues: 1.3B USD
4.5%
Evenity: 1.2B USD
4.1%
Vectibix: 984m USD
3.5%
Blincyto: 861m USD
3.1%
Tepezza: 448m USD
1.6%
Krystexxa: 272m USD
1%
Product Sales: 180m USD
0.6%
Show More
Show Less

See Also

What is Amgen Inc's Revenue?
Revenue
28.2B USD

Based on the financial report for Dec 31, 2023, Amgen Inc's Revenue amounts to 28.2B USD.

What is Amgen Inc's Revenue growth rate?
Revenue CAGR 10Y
4%

Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Amgen Inc have been 4% over the past three years , 3% over the past five years , and 4% over the past ten years .

ALPHA SPREAD
Join more than 133,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.